Avandia's Black Box: FDA's Office of New Drugs Wins
This article was originally published in RPM Report
Executive Summary
The decision by FDA to add another "black box" warning to GalxoSmithKline's diabetes drug shows where the drug safety group stands on the agency's totem pole.